Visceral adiposity index is associated with benign prostatic enlargement in non-diabetic patients: a cross-sectional study

References

• Berry SJ, Coffey DS, Walsh PC, et al. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132:474–479.
   PubMed Web of Science ®Google Scholar
• Lee C, Kozlowski JM, Grayhack JT. Etiology of benign prostatic hyperplasia. Urol Clin North Am. 1995;22:237–246.
   PubMed Web of Science ®Google Scholar
• Donnell RF. Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Curr Opin Urol. 2011;21:22–26.
   PubMed Web of Science ®Google Scholar
• Grosman H, Fabre B, Mesch V, et al. Lipoproteins, sex hormones and inflammatory markers in association with prostate cancer. Aging Male. 2010;13:87–92.
   PubMed Web of Science ®Google Scholar
• Fu Y, Zhou Z, Yang B, et al. The relationship between the clinical progression of benign prostatic hyperplasia and metabolic syndrome: a prospective study. Urol Int. 2016;97:330–335.
   PubMed Web of Science ®Google Scholar
• Wang JY, Fu YY, Kang DY. The association between metabolic syndrome and characteristics of benign prostatic hyperplasia: a systematic review and meta-analysis. Medicine. 2016;95:e3243.
   PubMed Web of Science ®Google Scholar
• Zou C, Gong D, Fang N, et al. Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients. World J Urol. 2016;34:281–289.
   PubMed Web of Science ®Google Scholar
• Pascot A, Lemieux S, Lemieux I, et al. Age-related increase in visceral adipose tissue and body fat and the metabolic risk profile of premenopausal women. Diabetes Care. 1999;22:1471–1478.
   PubMed Web of Science ®Google Scholar
• DeNino WF, Tchernof A, Dionne IJ, et al. Contribution of abdominal adiposity to age-related differences in insulin sensitivity and plasma lipids in healthy nonobese women. Diabetes Care. 2001; 24:925–932.
   PubMed Web of Science ®Google Scholar
• Amato MC, Giordano C, Galia M, et al. Visceral adiposity index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care. 2010;33:920–922.
   PubMed Web of Science ®Google Scholar
• Lv X, Zhou W, Sun J, et al. Visceral adiposity is significantly associated with type 2 diabetes in middle-aged and elderly Chinese women: a cross-sectional study. J Diabetes. 2016; DOI: 10.1111/1753-0407.12499.
   Web of Science ®Google Scholar
• Guo SX, Zhang XH, Zhang JY, et al. Visceral adiposity and anthropometric indicators as screening tools of metabolic syndrome among low income rural adults in Xinjiang. Sci Rep. 2016; DOI: 10.1038/srep36091.
   Web of Science ®Google Scholar
• Parsons JK. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol. 2007;178:395–401.
   PubMed Web of Science ®Google Scholar
• Parsons JK, Sarma AV, McVary K, et al. Obesity and benign prostatic hyperplasia: clinical connections, emerging etiological paradigms and future directions. J Urol. 2009;182: S27–S31.
   PubMed Web of Science ®Google Scholar
• Nandeesha H. Benign prostatic hyperplasia: dietary and metabolic risk factors. Int Urol Nephrol. 2008;40:649–656.
   PubMed Web of Science ®Google Scholar
• Seim A, Hoyo C, Ostbye T, et al. The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study. BJU Int. 2005;96:88–92.
   PubMed Web of Science ®Google Scholar
• Kristal AR, Arnold KB, Schenk JM, et al. Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. J Urol. 2007;177:1395–1400.
   PubMed Web of Science ®Google Scholar
• Dahle SE, Chokkalingam AP, Gao YT, et al. Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia. J Urol. 2002;168:599–604.
   PubMed Web of Science ®Google Scholar
• Lee RK, Chung D, Chughtai B, et al. Central obesity as measured by waist circumference is predictive of severity of lower urinary tract symptoms. BJU Int. 2012;110:540–545.
   PubMed Web of Science ®Google Scholar
• Zucchetto A, Tavani A, Dal Maso L, et al. History of weight and obesity through life and risk of benign prostatic hyperplasia. Int J Obes. 2005;29:798–803.
   PubMed Web of Science ®Google Scholar
• Khoo J, Piantadosi C, Worthley S, et al. Effects of a low-energy diet on sexual function and lower urinary tract symptoms in obese men. Int J Obes. 2010;34:1396–1403.
   PubMed Web of Science ®Google Scholar
• Joseph MA, Harlow SD, Wei JT, et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol. 2003;157:906–914.
   PubMed Web of Science ®Google Scholar
• Lee S, Min HG, Choi SH, et al. Central obesity as a risk factor for prostatic hyperplasia. Obesity (Silver Spring). 2006;14:172–179.
   PubMed Web of Science ®Google Scholar
• Sarma AV, Jaffe CA, Schottenfeld D, et al. Insulin-like growth factor-1, insulin-like growth factor binding protein-3 and body mass index: clinical correlates of prostate volume among black men. Urology. 2002;59:362–367.
   PubMed Web of Science ®Google Scholar
• Freedland SJ, Platz EA, Presti JC Jr, et al. Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol. 2006;175:500–504.
   PubMedGoogle Scholar
• Hammarsten J, Damber JE, Karlsson M, et al. Insulin and free oestradiol are independent risk factors for benign prostatic hyperplasia. Prostate Cancer Prostatic Dis. 2009;12:160–165.
   PubMed Web of Science ®Google Scholar
• Nandeesha H, Koner BC, Dorairajan LN, et al. Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia. Clin Chim Acta. 2006;370:89–93.
   PubMed Web of Science ®Google Scholar
• Ding EL, Song Y, Malik VS, et al. Sex differences of endogenous sex hormones and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2006;295:1288–1299.
   PubMed Web of Science ®Google Scholar
• Aktas BK, Gokkaya CS, Bulut S, et al. Impact of metabolic syndrome on erectile dysfunction and lower urinary tract symptoms in benign prostatic hyperplasia patients. Aging Male. 2011;14:48–52.
   PubMed Web of Science ®Google Scholar
• Ebrahimi F, Christ-Crain M. Metabolic syndrome and hypogonadism-two peas in a pod. Swiss Med Wkly. 2016;21:w14283.
   Google Scholar
• Canguven O, Talib RA, El Ansari W, et al. Testosterone therapy has positive effects on anthropometric measures, metabolic syndrome components (obesity, lipid profile, Diabetes Mellitus control), blood indices, liver enzymes and prostate health indicators in elderly hypogonadal men. Andrologia. 2017; DOI: 10.1111/and.12768.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• Yassin DJ, Doros G, Hammerer PG, et al. Long-term testosterone treatment in elderly men with hypogonadism and erectile dysfunction reduces obesity parameters and improves metabolic syndrome and health-related quality of life. J Sex Med. 2014;11:1567–1576.
   PubMed Web of Science ®Google Scholar
• Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male. 2011;14:53–58.
   PubMed Web of Science ®Google Scholar
• Canguven O, Talib RA, El Ansari W, et al. Vitamin D treatment improves levels of sexual hormones, metabolic parameters and erectile function in middle-aged vitamin D deficient men. Aging Male. 2017;20:9–16.
   PubMed Web of Science ®Google Scholar
• Park SG, Yeo JK, Cho DY, et al. Impact of metabolic status on the association of serum vitamin D with hypogonadism and lower urinary tract symptoms/benign prostatic hyperplasia. Aging Male. 2017;17:1–5.
   Web of Science ®Google Scholar